Michael Mogadam, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Mogadam M.; Transdermal Nicotine for Ulcerative Colitis. Ann Intern Med. 1997;127:491. doi: 10.7326/0003-4819-127-6-199709150-00018
Download citation file:
Published: Ann Intern Med. 1997;127(6):491.
TO THE EDITOR:
Sandborn and colleagues  state that their placebo-controlled trial showed that “transdermal nicotine at the highest tolerated dosage (≤22 mg/d) has a clinically significant therapeutic benefit in active ulcerative colitis after 4 weeks.” How could they make this statement if only 39% of their patients improved clinically (compared with 9% of those who received placebo)? I do not consider a 30% response (39% −9%) in ulcerative colitis to be clinically meaningful, especially because 77% of patients who received nicotine patches had various side effects; in 13%, these effects were severe enough to discontinue use of the patches.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only